IPOX® Health Innovation Index (IPHI)

The IPOX® Health Innovation Index (IPHI) is a diverse and dynamic portfolio consisting of leading companies in the healthcare and biotechnology sectors, focusing on recent listings (e.g. IPOs, Spin-Offs and SPACs) as well as acquirers of biotech innovation (“IPO M&As”). Using this strategy, the index captures the performance of both established and emerging players focused on innovative solutions, novel therapies, and cutting-edge medical technologies.

Key Features:

  • Innovation Focus: Targets companies at the forefront of healthcare advancements, from novel drug development to transformative medical technologies and services.

  • Diverse Exposure: Includes a mix of established large-cap pharmaceutical and healthcare leaders alongside dynamic small and mid-cap innovators.

  • Global Reach: Represents health innovation across key global markets, including North America, Europe, and Asia.

  • Rules-Based Methodology: Employs IPOX's proprietary technology to identify and weight constituents based on market cap, liquidity, and strategic M&A activity, rebalancing quarterly.

Health Innovation Themes in Focus

Global Leaders & Strategic Acquirers

The index is anchored by established global healthcare giants that provide stability and often act as strategic acquirers of innovation. These include major pharmaceutical companies like AbbVie, Amgen, and Roche, alongside diversified healthcare leaders such as Abbott Laboratories. Reflecting the index’s emphasis on recent listings and corporate actions, we also include companies like Sandoz Group (a 2023 Novartis spin-off and global leader in generics and biosimilars), as well as innovation-driven large caps such as Gilead Sciences, Takeda Pharmaceutical, and Astellas Pharma that actively invest in next-generation therapies.

Biotech Frontiers: Advancing Novel Therapies

A core component of the index represents the cutting edge of biotechnology, featuring companies developing novel therapies for unmet medical needs. Examples include BridgeBio Pharma (genetic diseases) and Legend Biotech (cell therapies in oncology), alongside emerging innovators such as Avidity Biosciences (antibody–oligonucleotide conjugates for rare muscle diseases), Merus (bispecific antibodies in oncology), Verona Pharma (treatments for respiratory disease), and Telix Pharmaceuticals (theranostic radiopharmaceuticals). This segment captures the high-growth potential of breakthroughs in biological science.

MedTech & Health Services Innovation

Beyond therapeutics, the index captures innovation in medical technology, diagnostics, and healthcare services. This includes Stryker (global med-tech), GE HealthCare (imaging, ultrasound, monitoring and diagnostics), Smith & Nephew (orthopedics, sports medicine and advanced wound care), Fresenius Medical Care (global dialysis products and services), HealthEquity (HSA administration platform), Waystar (healthcare payments automation), SCHOTT Pharma (drug-containment and delivery systems such as prefillable syringes), and Diagnostyka SA (leading Polish medical laboratory network). These companies are transforming how healthcare is delivered, managed, and accessed.

The IPOX® Health Innovation Index offers investors a unique way to access the broad spectrum of healthcare innovation, from foundational large-cap players to the next generation of biotech and medtech leaders. Its dynamic approach aims to capture the companies shaping the future of global health.

Contact info@ipox.com for licensing and sub-advisory opportunities.